Clinical trialNCT02272790CompletedPhase 2Interventional

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

SponsorAstraZenecaEnrollment95Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kathleen Moore, MD
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Research Site
Toronto, Ontario, Canada

Netherlands

Research Site
Amsterdam, Netherlands

United States

Research Site
Gilbert, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
La Jolla, California, United States
Research Site
Los Angeles, California, United States
Research Site
San Francisco, California, United States
Research Site
Tampa, Florida, United States
Research Site
West Palm Beach, Florida, United States
Research Site
Augusta, Georgia, United States
Research Site
Boston, Massachusetts, United States
Research Site
Detroit, Michigan, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Cleveland, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Abington, Pennsylvania, United States
Research Site
Nashville, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MK 1775Carboplatin →Gemcitabine →1-Dodecylpyridoxal chloridePaclitaxel →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jan 2015
Primary completion: 13 Dec 2018
Completion: 8 Mar 2023
Last update posted: 3 Oct 2023
Registered enrollment: 95
Registry id: NCT02272790

Cross-registrations

EU-CTR / CTIS (EudraCT)2015-000886-30

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.